Navigation Links
Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published

er of resistant clones.

According to Professor Lundgren, "It is widely known that melanoma cells often develop resistance to recombinant alpha interferon therapies. We observed dramatically different outcomes when comparing Multiferon(R) against Intron(R) A in human melanoma cell lines in vitro, with Multiferon(R) clearly suppressing resistance development far more efficiently than Intron(R) A after four weeks of treatment. One possibility is that multiple subtypes of alpha interferon in Multiferon(R) are working synergistically to eradicate resistant cell clones. If Multiferon(R) is indeed suppressing the development of resistant melanoma clones, this effect may have played a role in improving overall survival in melanoma patients in Viragen's previously reported Phase II/III melanoma trial, published last year in Acta Oncologica."

In February 2006, Multiferon(R) was approved in Sweden for the first-line adjuvant treatment of high-risk malignant melanoma. Viragen is preparing to proceed with a European Union (EU) regulatory process for Multiferon(R), through a registration pathway called the Mutual Recognition Procedure (MRP). This procedure allows a single registration dossier to be filed for approval among a targeted group of EU countries via one application and review process.

* Intron(R) A is registered trademark of Schering-Plough Corporation

About Malignant Melanoma:

Skin cancer is the most common type of cancer, accounting for more than 50% of all cancers. Melanoma accounts for approximately 4% of skin cancer cases, but causes 79% of skin cancer deaths. The American Cancer Society estimates that in 2006 there were 62,190 new cases of melanoma in the United States and about 7,910 people died of this disease.

About Multiferon(R):

Alpha interferon is produced by the human immune system and helps improve the body's natural resistance to disease.

Multiferon(R) differs from single-subtype recombinant alpha in
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:5/4/2015)... CARLSBAD, Calif. , May 4, 2015  Isis ... an exclusive license agreement with Bayer HealthCare (Bayer) to ... of thrombosis. Under the terms of the agreement, Isis ... near-term payments, including an immediate $100 million up-front payment ... program following a Phase 2 study in patients with ...
(Date:5/4/2015)... 4, 2015 MEI Pharma, Inc. (Nasdaq: ... the clinical development of novel therapies for cancer, ... of the Company,s investigational drug candidate ME-344 in ... combined with a tyrosine-kinase inhibitor (TKI). In addition, ... a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) ...
(Date:5/4/2015)... of the cuvette manufacturing world, opened their doors to the public in early 2015.  ... offering scientists amazing support for their spectroscopy needs.  ... ... ... In mid-2014 Simcha Woitovich ...
Breaking Medicine Technology:Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 2MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 3MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 4MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies 5New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3
(Date:5/4/2015)... 04, 2015 Malibu Biotech Systems ... breath spray. KissSafe™ is the first personal hygiene ... experience while adding fresh breath appeal. KissSafe™ contains ... kills germs in the mouth and oral cavity ... ingredients that possess additional wellness benefits. KissSafe’s proprietary ...
(Date:5/4/2015)... May 04, 2015 Milton Hershey School® ... 2015 Alumnus of the Year, recognizing his commitment to ... philanthropy he sets for MHS students. , “Dr. Graves ... happen when children are provided a top-notch education, a ... their passions,” said Pete Gurt ’85, president of MHS. ...
(Date:5/4/2015)... PROVIDENCE, R.I. (PRWEB) May 04, 2015 Johnson ... new $40 million engineering and science academic center on Wednesday, ... in the ground for land made available by the re-alignment ... at the corner of Friendship and Chestnut streets in Providence, ... being built on a parcel of land the university purchased ...
(Date:5/4/2015)... The opportunity for children to dream of a bright ... behind The Fairy Godmother Next Door, a new children’s picture ... , The inspiration for the enchanting story of a fairy ... desire to be a fairy godmother. , “My wish came ... neighbors’ children since they were born. We discuss fairies and ...
(Date:5/4/2015)... NORTH HOLLYWOOD, Calif. (PRWEB) May 04, 2015 ... awards program recognizes IPC clinical leaders who have made ... to the patients they serve, both in acute and ... Hospitalist of the Year, Post-Acute Provider of the Year, ... the Year and Specialist Provider of the Year. Recipients ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:IPC Healthcare Announces Clinicians of the Year 2Health News:IPC Healthcare Announces Clinicians of the Year 3
... behaviors, study says , , THURSDAY, Nov. 6 (HealthDay News) ... much lower in areas that have lots of green ... large British study finds. , Dr. Richard Mitchell, of ... previous studies have shown that the presence of green ...
... Calif., Nov. 6 Lumenis(R) Ltd. a global,developer, ... for ophthalmic, surgical and aesthetic applications,announced today that ... devices on November 8th at the American Academy ... Dov Ofer, Lumenis, President and Chief Executive Officer ...
... of veterans with posttraumatic stress disorder (PTSD) raises the ... and children in communities across the United States," says ... and an assistant professor of social work at Washington ... are very different than those for PTSD. The Department ...
... Texas, Nov. 6 The following was released ... A recent report from the U.S. Department of ... 08-01105-171) substantiated waste,mismanagement and inaction to disclosures of ... Central Texas Veterans Health,Care System (CTVHCS)., Inaction ...
... 6 Savient,Pharmaceuticals, Inc. (Nasdaq: SVNT ) ... Officer of Savient Pharmaceuticals,will present a corporate update ... The presentation is scheduled to begin on November ... The Conference will be held at the Arizona,Biltmore ...
... 6 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ), ... anti-infective products, today,announced that three patents protecting Moxatag ... Orange Book on,Oct. 24, 2008, pursuant to Section ... on Oct. 8, 2008., MiddleBrook President & ...
Cached Medicine News:Health News:Green Areas Lower Health Inequities Between Rich, Poor 2Health News:Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA 2Health News:Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA 3Health News:Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA 4Health News:Growing problem for veterans: Domestic violence 2Health News:War Veterans With Traumatic Brain Injury Pay the Price of Waste at the VA, Says Dr. Robert Van Boven 2Health News:Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th 2Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 2Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 3Health News:MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: